Prox Ventures
VC Fund
Shanghai, China
Prox Ventures is a VC fund in Shanghai focused on Medical and Biotechnology. Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
- Total investments:
- 83
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Prox Ventures invests in
Stages Prox Ventures invests in
Countries Prox Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2.5M–$30M
- Series A
- $3M–$28M
Investment Focus
Industry
- Medical 36 (43%)
- Biotechnology 32 (39%)
- Health Care 25 (30%)
- Medical Device 20 (24%)
- Life Science 13 (16%)
Stage
- Seed 27 (33%)
- Series A 15 (18%)
- Funding Round 12 (14%)
- Venture - Series Unknown 10 (12%)
- Series B 7 (8%)
Country
- China 47 (57%)
- United States 10 (12%)
- United Kingdom 2 (2%)
- France 1 (1%)
- Hong Kong 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Florian Brand
Founder
|
Founder | Total investments: 4 | Find email | |
|
Li Qian
Project leader
|
Project leader | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications. | $29.9M / Seed / Sep 22, 2026 | ||
| Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials. | $14.8M / Series A / Jun 02, 2026 | ||
| Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments. | Series A / Feb 09, 2026 | ||
|
Shengxin Medical
|
Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency. | Series A / Nov 21, 2025 | |
Brise Pharma
|
Brise Pharma operates in the scientific research and technical service industry. | $28.1M / Series A / Nov 11, 2025 | |
| BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $28M / Series B / Oct 16, 2025 | ||
| Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M / Series A / Sep 04, 2025 | ||
| InxMed is a clinical-stage biotech company focusing on developing "Best-in-Disease Combination" medicines to bring novel treatment options for patients. Our innovations are inspired by patients and driven by an in-depth understanding of disease biology and pharmacology. InxMed is committed to building a translational platform equippedwith global-level top-notch know-how and efficient execution capabilities. | $34M / Series C / Aug 22, 2025 | ||
Tuanxiang Pharmaceutical
|
Tuanxiang Pharmaceutical is an innovative drug research and development company that combines traditional new drug research and development with the use of the world's leading unique phase separation technology. | Seed / Feb 24, 2025 | |
| LinkZill is a high-tech firm with products such as organic semiconductor materials, thin-film transistors, array, and portable test systems. | Series A / Feb 14, 2025 | ||
| See all 83 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Prox Ventures invest in?
Prox Ventures invests primarily in Medical, Biotechnology and Health Care startups, most often at Seed and Series A stage. Most of the 83 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Prox Ventures's check size?
Prox Ventures typically joins rounds of $2.5M–$30M at Seed and $3M–$28M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Prox Ventures participates in.
How do I contact Prox Ventures?
Public channels for Prox Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Prox Ventures?
The team at Prox Ventures includes Florian Brand (Founder) and Li Qian (Project leader). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
